BiotechTube
RoslinCT

RoslinCT

Edinburgh, United Kingdom· Est.
roslinct.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

RoslinCT is a globally operating, private CDMO focused exclusively on cell and gene therapies, with deep scientific roots in the pioneering work of the Roslin Institute. It offers a full suite of services including cGMP iPSC development, cell banking, process development, and manufacturing across 22+ cGMP suites in the US and EU. The company has a proven track record, notably collaborating with Vertex Pharmaceuticals on the commercial CRISPR therapy exa-cel, and serves a diverse pipeline of client programs from clinical to commercial stages.

OncologyRare Genetic DiseasesHematology

Technology Platform

Integrated CDMO platform specializing in cGMP iPSC development, process/analytical development, cell banking, and manufacturing for autologous and allogeneic cell & gene therapies, with expertise in CRISPR-edited therapies.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

Explosive growth in the cell & gene therapy market drives sustained demand for specialized CDMO capacity.
RoslinCT's pioneering expertise in iPSCs and proven commercial-scale experience with CRISPR therapies positions it ideally to capture high-value allogeneic and gene-edited therapy programs.
Geographic expansion in the US and EU provides access to the world's two largest pharmaceutical markets.

Risk Factors

Revenue dependency on a limited number of key clients (e.g., Vertex) creates concentration risk.
The highly complex and variable nature of cell therapy manufacturing carries significant technical and operational risks, including potential batch failures.
Intensifying competition from both large CDMOs and new entrants could pressure pricing and margins.

Competitive Landscape

RoslinCT competes in the specialized CGT CDMO space against pure-play rivals like Lonza's Cell & Gene Therapy business, Catalent's Cell & Gene Therapy unit, and Oxford Biomedica Solutions, as well as larger diversified CDMOs (e.g., Thermo Fisher Scientific/Patheon) expanding into the area. Its key differentiators are its deep iPSC heritage, proven commercial CRISPR manufacturing experience, and integrated software solutions for therapy management.

More companies in Cell & Gene Therapy →More companies in United Kingdom →